Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients

Show other versions (1)

Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is mediated by different mechanisms that can be classified as <em>BCR-ABL</em> dependent or <em>BCR-ABL</em> independent pathways. <em>BCR-ABL</em> dependent mechanisms...

Full description

Bibliographic Details
Main Authors: Marjanu Hikmah Elias, Abdul Aziz Baba, Azlan Husin, Abu Dzarr Abdullah, Rosline Hassan, Goh Ai Sim, S. Fadilah Abdul Wahid, Ravindran Ankathil
Format: Article
Language:English
Published: PAGEPress Publications 2012-11-01
Series:Hematology Reports
Subjects:
chronic myeloid leukemia, imatinib mesylate, BCR-ABL dependent mechanisms, tyrosine kinase domain, mutation
Online Access:http://www.pagepress.org/journals/index.php/hr/article/view/4413

Internet

http://www.pagepress.org/journals/index.php/hr/article/view/4413

Similar Items